Publications by authors named "Michel Giunta"
What's New in Ocular Drug Delivery: Advances in Suprachoroidal Injection since 2023.
Pharmaceuticals (Basel)
July 2024
Despite significant advancements in ocular drug delivery, challenges persist in treating posterior segment diseases like macular edema (ME) and age-related macular degeneration (AMD). Suprachoroidal (SC) injections are a promising new method for targeted drug delivery to the posterior segment of the eye, providing direct access to the choroid and retina while minimizing systemic exposure and side effects. This review examines the anatomical and physiological foundations of the SC space; evaluates delivery devices such as microcatheters, hypodermic needles, and microneedles; and discusses pharmacokinetic principles.
View Article and Find Full Text PDFDespite advances in systemic care, diabetic disease of the eye (DDE) remains the leading cause of blindness worldwide. There is a critical gap of up-to-date, evidence-based guidance for ophthalmologists in Canada that includes evidence from recent randomized controlled trials. Previous guidance has not always given special consideration to applying treatments and managing DDE in the context of the healthcare system.
View Article and Find Full Text PDFHydrogels in Ophthalmology: Novel Strategies for Overcoming Therapeutic Challenges.
Materials (Basel)
December 2023
Article Synopsis
- The intricate design of the human eye requires specialized approaches for treating eye diseases, leading to recent interest in hydrogels as a therapeutic option.
- Hydrogels have been highlighted for their benefits in drug delivery to the back of the eye and in enhancing intraocular lens technology over the past five years.
- Although hydrogels show great promise for targeted drug release and improved patient outcomes, most studies are still in preclinical stages, necessitating thorough clinical evaluations before widespread use.
Purpose: To assess early real-world outcomes with brolucizumab in Canadian patients with neovascular age-related macular degeneration (nAMD) for which they previously received ≥1 anti-vascular endothelial growth factor (anti-VEGF) agent(s).
Patients And Methods: This multisite, real-world, retrospective chart review included data from a consecutive sample of 73 patients who received brolucizumab for nAMD after treatment with ≥1 other anti-VEGF agents. The principal reasons for switching to brolucizumab were to extend the treatment interval (51.